114 related articles for article (PubMed ID: 30590286)
1. Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
J Affect Disord; 2019 Mar; 246():241-247. PubMed ID: 30590286
[TBL] [Abstract][Full Text] [Related]
2. Functional connectivity of the amygdala subregions and the antidepressant effects of repeated ketamine infusions in major depressive disorder.
Liu H; Wang C; Lan X; Li W; Zhang F; Hu Z; Ye Y; Ning Y; Zhou Y
Eur Psychiatry; 2024 Apr; 67(1):e33. PubMed ID: 38572583
[TBL] [Abstract][Full Text] [Related]
3. Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial.
Lan X; Wang C; Zhang F; Liu H; Li W; Ye Y; Hu Z; Mai S; Ning Y; Zhou Y
Child Adolesc Psychiatry Ment Health; 2023 Sep; 17(1):108. PubMed ID: 37710297
[TBL] [Abstract][Full Text] [Related]
4. Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder.
Davis MT; DellaGiogia N; Maruff P; Pietrzak RH; Esterlis I
Transl Psychiatry; 2021 Apr; 11(1):205. PubMed ID: 33833217
[TBL] [Abstract][Full Text] [Related]
5. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.
Murrough JW; Wan LB; Iacoviello B; Collins KA; Solon C; Glicksberg B; Perez AM; Mathew SJ; Charney DS; Iosifescu DV; Burdick KE
Psychopharmacology (Berl); 2013 Sep; ():. PubMed ID: 24022236
[TBL] [Abstract][Full Text] [Related]
6. Comment on: "Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial".
Kwaśna J; Kwaśny A; Bychowski M; Kwaśna M; Pastuszak M
Psychiatry Res; 2024 Jul; 337():115987. PubMed ID: 38820654
[No Abstract] [Full Text] [Related]
7. Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial.
Singh B; Parikh SV; Voort JLV; Pazdernik VK; Achtyes ED; Goes FS; Yocum AK; Nykamp L; Becerra A; Smart L; Greden JF; Bobo WV; Frye MA; Burdick KE; Ryan KA
Psychiatry Res; 2024 May; 335():115829. PubMed ID: 38479192
[TBL] [Abstract][Full Text] [Related]
8. Sex differences in the effects of repeated ketamine infusions on bone markers in patients with unipolar and bipolar depression.
Lan X; Liu H; Wang C; Li W; Zhang F; Hu Z; Chen X; You Z; Ning Y; Zhou Y
Biol Sex Differ; 2024 Jan; 15(1):12. PubMed ID: 38287453
[TBL] [Abstract][Full Text] [Related]
9. Synergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: a pilot study.
Shanok NA; Muzac S; Brown L; Barrera M; Rodriguez R
Psychopharmacology (Berl); 2024 Jul; 241(7):1427-1433. PubMed ID: 38472415
[TBL] [Abstract][Full Text] [Related]
10. Virtual reality working memory training improves cognitive performance of acute and remitted patients with major depressive disorder.
Yan S; Shen S; Lu Q; Zhong S; Lv S; Lai S; Luo Y; Ran H; Duan M; Song K; Ye K; Jia Y
J Affect Disord; 2024 Jan; 344():267-276. PubMed ID: 37838265
[TBL] [Abstract][Full Text] [Related]
11. Baseline Plasma BDNF Levelsare Associated with Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Major Depressive Disorder.
Zheng W; Gu L; Zhou Y; Wang C; Lan X; Zhang B; Li Z; Ning Y
Curr Neuropharmacol; 2023; 21(4):1013-1021. PubMed ID: 36173064
[TBL] [Abstract][Full Text] [Related]
12. Intravenous ketamine for rapid treatment of major depressive disorder in the general medical hospital.
Gee SH; Wratten C; Cairns R; Santhouse A; Taylor D
BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34645623
[TBL] [Abstract][Full Text] [Related]
13. Ketamine for resistant depression: a scoping review.
Eduardo TQ; Angela A; Mateo L; Melanie LZ; Valentina PF; David C; Estefania C; Natalia RS; Andrés VC; Angel RO; Juan G; Juan P
Actas Esp Psiquiatr; 2022 May; 50(3):144-159. PubMed ID: 35643973
[TBL] [Abstract][Full Text] [Related]
14. Ketamine produces no detectable long-term positive or negative effects on cognitive flexibility or reinforcement learning of male rats.
Nist AN; Walsh SJ; Shahan TA
Psychopharmacology (Berl); 2024 Apr; 241(4):849-863. PubMed ID: 38062167
[TBL] [Abstract][Full Text] [Related]
15. Rapid-acting antidepressant drugs modulate affective bias in rats.
Hinchcliffe JK; Stuart SA; Wood CM; Bartlett J; Kamenish K; Arban R; Thomas CW; Selimbeyoglu A; Hurley S; Hengerer B; Gilmour G; Robinson ESJ
Sci Transl Med; 2024 Jan; 16(729):eadi2403. PubMed ID: 38198569
[TBL] [Abstract][Full Text] [Related]
16. Characterizing Major Depressive Disorder (MDD) using alpha-band activity in resting-state electroencephalogram (EEG) combined with MATRICS Consensus Cognitive Battery (MCCB).
Wang B; Li M; Haihambo N; Qiu Z; Sun M; Guo M; Zhao X; Han C
J Affect Disord; 2024 Jun; 355():254-264. PubMed ID: 38561155
[TBL] [Abstract][Full Text] [Related]
17. Changes in Mild Neurocognitive Disorder Status in Mobility Limited Older Primary Care Patients: Implications for Rehabilitative Care.
Ogawa EF; Ward RE; Milberg WP; Dufour AB; Moye J; Driver JA; Bean JF
Am J Phys Med Rehabil; 2023 Sep; 102(9):773-779. PubMed ID: 36753448
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Compatibility of Orally Administered Racemic Ketamine with Modafinil, a CYP3A4 Enzyme Inducer, in Treatment-Refractory Major Depressive Disorder.
Andrade C
Indian J Psychol Med; 2023 Nov; 45(6):651-653. PubMed ID: 38545532
[No Abstract] [Full Text] [Related]
19. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.
Salloum NC; Fava M; Freeman MP; Flynn M; Hoeppner B; Hock RS; Cusin C; Iosifescu DV; Trivedi MH; Sanacora G; Mathew SJ; Debattista C; Ionescu DF; Papakostas GI
Depress Anxiety; 2019 Mar; 36(3):235-243. PubMed ID: 30597688
[TBL] [Abstract][Full Text] [Related]
20. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Fava M; Freeman MP; Flynn M; Judge H; Hoeppner BB; Cusin C; Ionescu DF; Mathew SJ; Chang LC; Iosifescu DV; Murrough J; Debattista C; Schatzberg AF; Trivedi MH; Jha MK; Sanacora G; Wilkinson ST; Papakostas GI
Mol Psychiatry; 2020 Jul; 25(7):1604. PubMed ID: 30617276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
